Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Roche receives positive CHMP -2-

09/17/2021 | 07:10am EDT

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Blueprint Medicines, Gavreto and associated logos are trademarks of Blueprint Medicines Corporation.


[1] World Health Organization. Cancer [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G6PrjO8HlKwwgYiEYphMG5PI8MSf7x427BAaLaj3N3_CTcmJIGXFM_mp-69iilYL5kO6kXpzysQl7Y7UmzxM55Bfggi9w_xNT5Va39xJTH5-Ecn2UhKxivo-D0AuQHsorsEuYx7nc8TfBiDLi-85NEa8mBR0cRKNq_gmY-MQ7ktN https://www.who.int/news-room/fact-sheets/detail/cancer.

[2] American Cancer Society. Key Statistics for Lung Cancer [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G7ZWaTNk7psU-WGoGXoOjU2orMDp9cFD0_5AEyiGGIYIzWWbuxRPpfgVl9A5z46LnbhCfofz8q4gWWahemN_T6maJCg9S-i31jYlyZ10hjubTTjfYRV3xahJWTiAMzOtz08gzr9YqW3M9Hal0YCb36R8pLnYNMBx0LwUBC5IuZsp6ztzrEuIHZwpD45XzvuYGg== https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.

[3] Drilon A, et al. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. J Thorac Oncol. 2018;13:1595-601.

[4] Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019 Aug 1;30(8):1321-1328.

[5] Sabari J, et al. RET-rearranged lung cancers: Immunophenotype and response to immunotherapy. Journal of Clinical Oncology. 2018;36:9034-9034.

[6] Subbiah V, et al. Precision Targeted Therapy with BLU-667 for RET -Driven Cancers. Cancer Discov. 2018;8:836-849.

[7] Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):e120858.

[8] Gainor J, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. The Lancet. 2021;S1470-2045(21)00247-3.

[9] Subbiah V, et al. Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021; 04-08 Jun, 2021. Abstract #3079.

[10] ClinicalTrials.gov. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) [Internet; cited 2021 Sept]. Available from: https://www.globenewswire.com/Tracker?data=x1SQlQop7a9ZRhEkalD0G-PEQIoOIRyzmITzr0vNUMimrwPZHP_N1ygqR0VI2cqwnQYbH_h_vgNuCixeeUM011G_KRRemn3nJgzVf6HBaoRcS4ExYWC5Hsq3THu3inkSLNqe6MR4lv3SEYe1SoXaFY2tjqQ9Rf_yHPLS4mIE154= https://clinicaltrials.gov/ct2/show/NCT03037385.

[11] Curigliano G. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021; 04-08 Jun, 2021. Abstract #9089.

[12] Santoro M, et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes. 2020;11(4):424.

[13] Romei C, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget. 2018;9(11):9875-84.

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: https://www.globenewswire.com/Tracker?data=qpSCSQiZ5I9zB3TMdwRmU2JDOMzLUiOEWHUhdm44QpDwJQEV-wCI8g032ribuiTOoTB9XwLc0xomyXJpgMiB-XWPy3xxUTz9kWsNuOwgsIw= media.re https://www.globenewswire.com/Tracker?data=dKm22DD6Kagl8Q9qNtzfv2rbcySpnmqeDaZtW1jBTR3Q_MuAVhuIRjggpH2gwWe5ARpLDBOfCOrE2Gifwmo6KU_scQaLw70NXL6YOW8201U= lations@roche.com

Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Nina Mählitz           Karsten Kleine 
 Phone: +41 79 327 54 74     Phone: +41 61 682 28 31 
Dr. Barbara von Schnurbein  Nathalie Meetz 
 Phone: +41 61 687 89 67     Phone: +41 61 687 43 05 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: mailto:jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com                         jon_kaspar.bayard@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: mailto:bruno.eschli@roche.com 
 sabine.borngraeber@roche.com                  bruno.eschli@roche.com 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  ------------------------------------------- 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: +1 650 225 3217                        Phone: +1 650 467 8737 
 e-mail: mailto:kalm.loren@gene.com            e-mail: mailto:tuomi.lisa@gene.com 
 kalm.loren@gene.com                           tuomi.lisa@gene.com 
--------------------------------------------  ------------------------------------------- 


   -- 17092021_MR_Gavreto CHMP 

(END) Dow Jones Newswires

September 17, 2021 07:10 ET (11:10 GMT)

All news about ROCHE HOLDING AG
05:28aROCHE : family shareholders will maintain stability - vice chairman
10/15ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E..
10/15ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea..
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq -2-
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people..
10/15GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
10/15ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists
10/15ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology..
10/15PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig..
10/14ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2021 61 787 M 66 909 M 66 909 M
Net income 2021 14 572 M 15 780 M 15 780 M
Net cash 2021 4 469 M 4 840 M 4 840 M
P/E ratio 2021 20,9x
Yield 2021 2,60%
Capitalization 313 B 339 B 339 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,86x
Nbr of Employees 101 465
Free-Float 83,5%
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 360,25 CHF
Average target price 382,53 CHF
Spread / Average Target 6,19%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.59%339 442
JOHNSON & JOHNSON2.49%424 619
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
MERCK & CO., INC.-4.24%198 283